These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 31401554)

  • 1. One-year outcomes of anti-vascular endothelial growth factor therapy in peripapillary choroidal neovascularisation.
    Singh SR; Fung AT; Fraser-Bell S; Lupidi M; Mohan S; Gabrielle PH; Zur D; Iglicki M; M López-Corell P; Gallego-Pinazo R; Farinha C; Lima LH; Mansour AM; Casella AM; Wu L; Silva R; Uwaydat SH; Govindahari V; Arevalo JF; Chhablani J
    Br J Ophthalmol; 2020 May; 104(5):678-683. PubMed ID: 31401554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of choroidal neovascularization with indocyanine green angiography in neovascular age-related macular degeneration subjects undergoing intravitreal bevacizumab therapy.
    Rush RB; Rush SW; Aragon AV; Ysasaga JE
    Am J Ophthalmol; 2014 Aug; 158(2):337-44. PubMed ID: 24844972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of choroidal neovascularization using intravitreal bevacizumab.
    Pedersen R; Soliman W; Lund-Andersen H; Larsen M
    Acta Ophthalmol Scand; 2007 Aug; 85(5):526-33. PubMed ID: 17511757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic factors for visual outcome after intravitreal anti-VEGF injection for naive myopic choroidal neovascularization.
    Yoon JU; Kim YM; Lee SJ; Byun YJ; Koh HJ
    Retina; 2012 May; 32(5):949-55. PubMed ID: 22534553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration at twenty-four months: the Pan-American Collaborative Retina Study.
    Arevalo JF; Sánchez JG; Wu L; Berrocal MH; Alezzandrini AA; Restrepo N; Maia M; Farah ME; Brito M; Díaz-Llopis M; Rodríguez FJ; Reategui G; Iturralde-Iraola J; Udaondo-Mirete P;
    Ophthalmology; 2010 Oct; 117(10):1974-81, 1981.e1. PubMed ID: 20569989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravitreal bevacizumab for choroidal neovascularization secondary to angioid streaks: a long-term follow-up study.
    Rosina C; Romano M; Cigada M; de Polo L; Staurenghi G; Bottoni F
    Eur J Ophthalmol; 2015; 25(1):47-50. PubMed ID: 25044143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors of eyes with naïve subfoveal myopic choroidal neovascularization after intravitreal bevacizumab.
    Yang HS; Kim JG; Kim JT; Joe SG
    Am J Ophthalmol; 2013 Dec; 156(6):1201-1210.e2. PubMed ID: 24075429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bevacizumab and triamcinolone acetonide for choroidal neovascularization due to age-related macular degeneration unresponsive to antivascular endothelial growth factors.
    Veritti D; Sarao V; Lanzetta P
    J Ocul Pharmacol Ther; 2013 May; 29(4):437-41. PubMed ID: 23215753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravitreal bevacizumab for the treatment of choroidal neovascularization secondary to angioid streaks: one year of follow-up.
    El Matri L; Kort F; Bouraoui R; Karim B; Chebil A; Chaker N
    Acta Ophthalmol; 2011 Nov; 89(7):641-6. PubMed ID: 21155980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Pro Re Nata Regimen with Anti-VEGF on Type 3 Macular Neovascularization: Long-Term Outcomes.
    Toto L; Viggiano P; Quarta A; Grassi M; De Nicola C; Aloia R; D'Aloisio R; Boscia G; Boscia F; Porreca A; Di Nicola M; Savastano MC; Mastropasqua R
    Ophthalmic Res; 2024; 67(1):282-291. PubMed ID: 38621369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. One-year outcomes of less frequent bevacizumab in age-related macular degeneration.
    Sonmez K; Sonmez PA; Ozkan SS; Atmaca LS
    Retina; 2011 Apr; 31(4):645-53. PubMed ID: 21358363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
    Arevalo JF; Fromow-Guerra J; Sanchez JG; Maia M; Berrocal MH; Wu L; Saravia MJ; Costa RA;
    Retina; 2008; 28(10):1387-94. PubMed ID: 18827735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravitreal bevacizumab for treatment-naïve subfoveal occult choroidal neovascularization in age-related macular degeneration.
    Furino C; Boscia F; Recchimurzo N; Besozzi G; Cardascia N; Sborgia L; Niro A; Sborgia C
    Acta Ophthalmol; 2009 Jun; 87(4):404-7. PubMed ID: 18782335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
    Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
    Retina; 2007; 27(4):432-8. PubMed ID: 17420694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration.
    Bashshur ZF; Bazarbachi A; Schakal A; Haddad ZA; El Haibi CP; Noureddin BN
    Am J Ophthalmol; 2006 Jul; 142(1):1-9. PubMed ID: 16815245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravitreal anti-vascular endothelial growth factor therapy versus photodynamic therapy for idiopathic choroidal neovascularization.
    Kang HM; Koh HJ
    Am J Ophthalmol; 2013 Apr; 155(4):713-9, 719.e1. PubMed ID: 23219069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravitreal bevacizumab for choroidal neovascularisation in serpiginous choroiditis.
    Parodi MB; Iacono P; La Spina C; Knutsson KA; Mansour A; Arevalo JF; Bandello F
    Br J Ophthalmol; 2014 Apr; 98(4):519-22. PubMed ID: 24414400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravitreal bevacizumab therapy on an as-per-needed basis in subfoveal choroidal neovascularization secondary to pathological myopia: 2-year outcomes of a prospective case series.
    Iacono P; Parodi MB; Papayannis A; Kontadakis S; Sheth S; Bandello F
    Retina; 2011 Oct; 31(9):1841-7. PubMed ID: 21775926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravitreal anti-VEGF therapy for choroidal neovascularisation secondary to pathological myopia: 4-year outcome.
    Ruiz-Moreno JM; Arias L; Montero JA; Carneiro A; Silva R
    Br J Ophthalmol; 2013 Nov; 97(11):1447-50. PubMed ID: 24026146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective study of treatment patterns and 1-year outcome of Asian age-related macular degeneration and polypoidal choroidal vasculopathy.
    Cheung CM; Li X; Mathur R; Lee SY; Chan CM; Yeo I; Loh BK; Williams R; Wong EY; Wong D; Wong TY
    PLoS One; 2014; 9(6):e101057. PubMed ID: 24978485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.